In cancers, maintenance of telomeres often occurs through activation of the catalytic subunit of telomerase, encoded by TERT . Yet, most cancers show only modest levels of telomerase gene expression, even in the context of activating hotspot promoter mutations (C228T and C250T).
INTRODUCTION
At the terminal ends of human chromosomes are telomere nucleoproteins, consisting of a hexameric DNA repeat, 5'-TTAGGG, coated by a complex of six shelterin proteins (1) .
Telomeres function as protective caps of chromosomes, safeguarding against genomic instability that can ensue if the exposed ends of chromosomes signaled DNA damage and repair responses. Following each round of cell division, telomeres shorten due to incomplete replication (2, 3) . Indeed, significant telomere shortening leads to replicative senescence (4) , essentially acting as barriers to uncontrolled cell division, while telomere dysfunction is sufficient to induce gross genomic instability (5) (6) . Most benign human somatic cells, except for stem cells in rapidly renewing tissues, lack the telomere-specific enzyme telomerase (7) , and therefore, are unable to extend and maintain telomeres. However, expressing the catalytic subunit of telomerase, TERT , is sufficient for telomerase activity and telomere extension, thus bypassing critical barriers to uncontrolled cell division (8, 9) .
A defining feature of cancer is limitless replicative potential (10) , which for the majority of cancers is facilitated, in part, by the activation of telomerase (11) (7) . Highly recurrent mutations (C228T and C250T) in the promoter region of TERT can drive TERT transcriptional activation and over-expression in cancer (12) (13) (14) . However, such mutations do not account for the majority of cancers with activated telomerase. In a survey of TERT promoter alterations in human cancers, more than 80% of cancers did not harbor TERT promoter mutations (15) . In these cancers with unaltered TERT promoter sequences, it is not always clear how TERT expression is activated. Interestingly, regardless of whether TERT is activated via promoter mutation or other mechanisms, the degree to which TERT is activated appears to be relatively modest, so much so that direct detection of TERT mRNA or protein expression using traditional in situ methods is uncommon in the majority of cancers (16, 17) .
The epigenetic regulation of telomerase expression is not fully characterized, and in particular, the role of DNA methylation of cytosine residues in the control of TERT expression remains unresolved. Canonically, promoter DNA methylation is thought to be a repressive chromatin mark, leading to silencing of cis-associated genes. However, there are interesting reports of contexts in which DNA methylation can lead to gene/chromatin activation (18, 19) . How DNA methylation may regulate TERT expression has been unclear, with multiple conflicting reports.
On the one hand, hypermethylation of a small cluster of CpG dinucleotides upstream of the TERT transcriptional start site (TSS) was implicated in conferring activation of TERT expression in cancer (20, 21) . However, other studies, including a study examining DNA methylation in cancers with promoter mutations, revealed that TERT promoter methylation behaved in the canonical fashion, with promoter methylation associated with silenced alleles, and lack of promoter methylation associated with expressed alleles (22, 23) . These conflicting reports may have arisen in part due to the technical challenges in measuring DNA methylation at the TERT promoter regions, which are characterized by very high GC content and CpG density, potentially leading to scant coverage of many relevant CpGs in the regulatory regions using previous methodologies.
Here, we have carried out the most comprehensive characterization of TERT promoter methylation to date by developing, extensively validating, and deploying ultra-deep bisulfite sequencing methods to measure DNA methylation at >310 CpGs within and surrounding the core TERT promoter in 96 different cell lines, including primary, immortalized, and malignant cells. We find that, generally, hypermethylation of TERT promoter sequences in cancer cells is associated with repressed chromatin/expression, and the remaining unmethylated alleles marked with open chromatin marks are largely responsible for the observed TERT expression in cancer cells. This association of unmethylated alleles with active expression and methylated alleles with silenced expression is particularly evident in cancers displaying allele specific expression, including cancers harboring recurrent promoter mutations. Overall, these findings suggest that TERT promoter hypermethylation in cancer cells may be involved in attenuating the degree of TERT activation in cancer cells.
RESULTS

Ultra-deep bisulfite sequencing of the TERT promoter CpG island in human cancer and normal cells
The promoter and proximal exons of TERT contain a CpG island with particularly high GC content (61.4% G or C, with a ratio of observed to expected CpG of 0.75) (24) (25) (26) (27) , which has greatly complicated experimental assessment of DNA methylation and other genetic and epigenetic alterations in a comprehensive manner. Whole genome bisulfite sequencing and other genome-scale methodologies often exhibit poor coverage across the entire region, and targeted approaches to overcome such challenges have not comprehensively covered the promoter CpG island around the first exon and upstream regions broadly. Here, we designed and optimized a series of highly overlapping bisulfite sequencing amplicons tiled across both plus and minus strands of the TERT promoter CpG island using a microwell, highly-parallel, microfluidics approach. Using this strategy, we were able to overcome these sequencing challenges and characterize the methylation of the TERT promoter at nucleotide-level resolution in 96 cell culture models, including 85 cancer lines, 6 immortalized lines, and 5 normal primary cell models (Table S1) , as well as a series of reference samples to validate the method .
Notably, the cancer cell lines investigated in this study included both cancer cells with wild type (WT) TERT promoters, and cancer cells that harbored highly recurrent TERT promoter mutations C228T or C250T. A subset of the cancer cell lines with WT TERT promoters employed the telomerase-independent, Alternative Lengthening of Telomeres (ALT) mechanism for telomere maintenance (28) . Expression of TERT , as assessed by RT-qPCR, confirmed low to no expression in primary and ALT-positive cancer cell models, while immortalized and telomerase-dependent, ALT-negative cancer cell lines had comparably higher TERT expression, particularly in the TERT -immortalized cell line models ( Figure S1 ) .
We interrogated the entire TERT promoter region and proximal exons, approximately -1300 base pairs (bp) upstream of the ATG and 2500 bp downstream. Using this bisulfite ultra-deep sequencing approach, we captured over 310 unique CpGs with redundancy by using more than 50 overlapping amplicons on both positive and negative strands ( Figure 1A) . The methylation measurements of our bisulfite ultra-deep sequencing approach were highly robust, with excellent reproducibility and precision in replicate samples including intra-and inter-batch controls ( Figure S2A ). Furthermore, our bisulfite ultra-deep sequencing measurements were highly concordant with conventional bisulfite Sanger sequencing measurements ( Figure S2B ) .
In our biological controls, methylation measurements were consistent with the known 5-methylcytosine (5mC) genomic content of the well-characterized cell lines, HCT116 DNMT1 KO , HCT116 DNMT3b KO , and HCT116 DKO, which is deficient in both DNMT1 and DNMT3b .
HCT116 DKO cells, known to harbor approximately 5% of the 5mC content of HCT116 WT cells (29) , showed significant hypomethylation compared to WT parental HCT116 cells.
Additionally, HCT116 cell line models deficient in either DNMT1 or DNMT3b, each known to harbor 60% and 80% reduced 5mC content compared to WT parental cells (29) , showed concordant levels of demethylation around the TERT promoter in our bisulfite ultra-deep sequencing data ( Figure S2C ) . Taken together, these analyses established that our approach provided robust and accurate methylation measurements across the TERT promoter.
In our expanded analysis of 96 different samples, we observed broadly that multiple large regions far upstream (chr5:1295338-1295731, hg19) and downstream (chr5:1294565-1294844, hg19) of the highly recurrent C228T and C250T mutations were nearly ubiquitously methylated ( Figure 1B) . The top 20% most variably methylated CpGs across all samples occurred in two major regions, one upstream of the location of the recurrent promoter mutations, and another downstream of exon 1, with high correlation of methylation within each of these regions ( Figure   S3A ) . Clustering samples by the top 20% most variable CpGs revealed that a cluster containing all of the non-malignant primary cells generally harbored less methylation than cancer cells ( Figure S3B ; Figure 1B ) . Indeed, identifying differentially methylated CpGs between cancer and normal samples indicated that, generally, the differentially methylated CpGs were more methylated in cancer compared to normal ( see rightward skew in Figure S4A ), with a significant fraction of these, including the top five, occuring in a region upstream of the hotspot mutations ( Figure S3B , Figure 1C ) .
We further validated these differential methylation patterns between cancer and non-malignant samples using previously published methylation microarray data. We compared our methylation assessment of a CpG residue that was also interrogated by the Infinium Methylation microarray platform (Infinium probe cg11625005, chr5:1295737, hg19) upstream of the TSS, which has been implicated as a marker of malignancy in cancer (20, 30, 31) . In our panel of cell line models, we found that cancer cells were generally more methylated than normal cells at this CpG.
Similarly, analysis of the publicly available TCGA data (32) confirmed that cancers were typically more methylated than normal at this CpG ( Figures S4B-C) .
Allele-Specific hypermethylation of wild-type alleles in C228T/C250T promoter mutant cancers.
We next identified CpGs that were differentially methylated between WT and TERT promoter mutant cancers. Interestingly, in general, the differentially methylated CpGs, including the top 5
CpGs, showed hypomethylation in the mutant compared to WT cancers, with many of these positions occurring just upstream of the position of the recurrent promoter mutations ( Figure   S5A ; Figure 1D ) .
Given the proximity of these differentially methylated CpGs in WT and mutant cancers to the position of the promoter mutations, we next assessed whether the mutant cancers exhibited allele-specific methylation of mutant or WT alleles. Although C -> T mutations can be difficult to assess in bisulfite sequencing data, we took advantage of the fact that we designed overlapping amplicons directed to the plus and minus strand separately and identified an amplicon (red arrow, Figure 1A ) that interrogated the G -> A mutation on the complementary strand, which would not be affected by bisulfite conversion. This amplicon allowed us to assess the mutation status of each sequenced allele, and also allowed phasing of the surrounding CpG methylation patterns with WT or mutant alleles ( Figure S5B ). Notably, this allowed, for the first time, phasing of CpG methylation to mutational status at single molecule resolution for each allele. Sanger sequencing of genomic DNA from a subset of the cell lines assessed in our study confirmed that our approach could accurately identify TERT promoter mutations from the bisulfite sequencing data ( Figure S5C ) . Our deep sequencing data from this amplicon revealed that nearly all promoter mutant cancers showed allele specific methylation of the WT allele and significantly reduced methylation of the mutant allele in a region upstream of the mutations (Figure 2A,B ) .
Six neighboring CpGs were found to be most differentially methylated in the amplicon containing highly recurrent TERT promoter mutations (Figure 2A) . Interestingly, the distribution of methylation of the WT alleles in mutant cell lines was similar to that of WT cell lines, with mutant alleles in the mutant cell lines being significantly hypomethylated ( Figure 2B, Figure S4A , Figure S5A ) .
To investigate this allele-specific methylation in greater detail, we selected representative cell lines with promoter mutations, and performed bisulfite Sanger sequencing of a larger region that could interrogate an increased number of CpGs upstream of the promoter mutations. These analyses confirmed allele-specific hypomethylation of mutant alleles compared to WT alleles in cancer cell line models with C228T or C250T TERT promoter mutations, namely, LOX-IMVI, M14, SNB19, and TSU-PR1 cells ( Figure 2C ) . Furthermore, the allele-specific methylation patterns of the six differentially methylated CpGs identified in the deep sequencing data were also found to be significantly differentially methylated between WT and mutant alleles in the bisulfite Sanger sequencing in these representative promoter mutant cell lines ( Figure 2D ) .
We assessed whether the reduced methylation seen in the mutant alleles compared to WT alleles translated to establishment of chromatin marks associated with active chromatin. In LOX-IMVI and M14 cells, we performed chromatin immunoprecipitation (ChIP) for epigenetic marks of active chromatin, H3K4me 3 and H3K27ac, followed by qPCR and Sanger sequencing of the products. These analyses revealed that mutant alleles were enriched for DNA hypomethylation, increased H3K4me 3 , and increased H3K27ac, while WT alleles were hypermethylated ( Figure 2D,E) . In the context of previous studies showing strong allele-specific expression of mutant alleles and lack of expression of WT alleles in mutant cancers (33, 34) , our results suggest that DNA hypermethylation is associated with transcriptionally silent WT alleles, while DNA hypomethylation is associated with active chromatin marks and transcription from mutant alleles.
Rare cell lines with predominantly mutant TERT promoters still maintain a balance of methylated repressed and unmethylated active alleles
It has been suggested that mutant TERT promoter alleles are undermethylated because they can prevent the polycomb complex and epigenetic machinery from promoting methylation of the adjacent sequence (22) . If this were the case, we would expect that the few cancers that have bi-allelic or hemizygous promoter mutations should be profoundly undermethylated in all alleles.
To examine this possibility, we used our deep sequencing data to identify four cell lines with >97% mutant allele fraction for the C228T or C250T mutations, indicating bi-allelic or hemizygous mutation: U251, HOP62, SK-MEL-2, and SF539. Sanger sequencing of genomic DNA confirmed that indeed U251 and HOP62 harbor predominantly mutant TERT promoter alleles ( Figure S7 ) validating the deep sequencing data in accurately identifying cell lines with bi-allelic/hemizygous promoter mutations.
Of these four cell lines, SK-MEL2 and SF539 had >80% of alleles with very low methylation as would be expected, a finding confirmed by bisulfite Sanger sequencing ( Figure S6 ). However, the other 2 cell lines, HOP62 and U251, harbored >55% of the mutated alleles showing increased methylation upstream of the mutation sites, with the remaining mutant alleles showing low methylation levels similar to that seen in the mutant alleles of cancers with mono-allelic mutation ( Figure 3 ). Subsequent bisulfite Sanger sequencing of SK-MEL-2 and HOP62 confirmed the contrasting methylation patterns identified in the deep sequencing data ( Figure   3B , Figure S6 ).
HOP62 and U251 thus represent interesting exceptions to the general trend that mutant alleles are undermethylated, suggesting that the presence of a mutation does not automatically lead to protection from DNA methylation. We hypothesized that, like other cancers with heterozygous mutations, the unmethylated and mutated alleles should be enriched for chromatin activation marks and be more selectively bound by the transcriptional machinery compared to the methylated and mutated alleles. To test this hypothesis, we carried out ChIP followed by qPCR and bisulfite sequencing in U251 cells. After confirming that the histone activation mark H3K4me3 and RNA Polymerase 2 (Pol2) were both highly enriched at the U251 TERT promoter using ChIP-qPCR ( Figure S8 ), we found that both of these chromatin activation factors were highly enriched for the unmethylated alleles using ChIP bisulfite sequencing ( Figure 3C ) . Taken together, these data suggest that some cancers with bi-allelic or hemizygous TERT promoter mutations still maintain a high fraction of methylated alleles, with only the remaining unmethylated alleles being associated with active chromatin and RNA Pol 2 binding.
Cells without promoter mutation show hypermethylation of inactive alleles and hypomethylation of active alleles.
In cancer cell lines with C228T/C250T promoter mutations and monoallelic expression, the mutant allele is expressed while the WT allele is repressed (33, 34) . However, cancer cell lines can also have monoallelic expression of TERT even in the absence of the C228T/C250T promoter mutations (34) . We examined, in cancers with monoallelic expression and WT TERT promoters, whether the non-expressed allele was selectively methylated. Among the cell lines analyzed in our sample set, RPMI-8226 was identified to have monoallelic expression. Sanger sequencing of genomic DNA confirmed that RPMI-8226 was indeed heterozygous for both A and G alleles of the rs2736098 SNP located in exon 2 of TERT ( Figure 4A ) , while Sanger sequencing of the cDNA derived from the TERT mRNA confirmed monoallelic expression of only the A allele ( Figure 4B ) . We performed long-range bisulfite amplicon Sanger sequencing (~1.5 kb), which encompassed the core TERT promoter, the region upstream of the highly recurrent promoter mutations, and the heterozygous rs2736098 SNP in order to phase the promoter DNA methylation pattern with the active vs. inactive allele ( Figure S9 ) . We observed that the expressed A allele phased with unmethylated sequences, while the repressed G allele phased with methylated sequences ( Figure 4C ) . The average methylation of the six most differentially methylated CpGs between mutant and WT alleles upstream of the highly recurrent TERT promoter mutations, originally identified in our deep sequencing data, showed significant difference between the A and G alleles, with the expressed A allele being hypomethylated and the repressed G allele being hypermethylated ( Figure 4D ) . This interesting example of a cancer with mono-allelic TERT expression provides further evidence that TERT promoter DNA methylation is associated with inactive alleles.
Methylation of TERT promoter sequences results in strong repression of heterologous reporter
constructs.
Finally, we assessed whether methylation of the TERT promoter, whether WT or mutant, would silence expression in a luciferase construct in multiple cell models, including Figure 5A ) . In these studies, a reporter construct driven by the glutathione S-transferase Pi 1 ( GSTP1 ) promoter were also included. The GSTP1 promoter is overlapped by a well characterized CpG island, and methylation of this promoter is known to silence gene expression (35) . HEK293T cells transfected with various deletion constructs of the TERT promoter driving luciferase expression showed activity similar to the control reporter construct driven by the GSTP1 promoter. The only exceptions were the deletion constructs that lacked elements of the core promoter, which showed reduced activity ( Figure 5B ) . As expected, methylation of the GSTP1 reporter construct inhibited expression. Likewise, methylation of all versions of the TERT promoter reporters inhibited expression ( Figure 5B ) . Similar observations were made when methylated and unmethylated reporter constructs were transfected in LNCaP and U2OS ( Figure S10 ) . Interestingly, reporter constructs driven by a C228T mutant promoter showed approximately 2-fold higher expression than reporter constructs with the WT TERT promoter. Methylation of the mutant reporter constructs abolished expression, independent of host cell TERT promoter mutational status ( Figure 5C ) . To confirm that methylation of the reporter construct was not dependent on methylation of CpGs outside of the promoter sequence, we used heterologous reporter constructs, pCpGL, in which the backbone plasmid sequence and reporter was engineered without CpGs (36) , such that only the TERT promoter would have CpGs. Methylation of these reporters showed uniform repression, independent of host cell. Additionally, we observed that the reporter driven by the C228T mutant promoter showed approximately 3-fold higher expression than the WT reporter construct, independent of host cell TERT promoter status ( Figure 5D ) . These functional data suggest that methylation of TERT promoters leads to strong transcriptional silencing regardless of mutation status.
DISCUSSION
In summary, our findings show that immortalized and cancer cell lines are generally hypermethylated in a region upstream of the recurrent C228T and C250T TERT promoter mutations, while normal primary cells are comparatively hypomethylated. These findings are consistent with previous reports describing hypermethylation of the CpG island spanning the TERT promoter in cancers compared to normal tissues (25, (37) (38) (39) (40) . However, at the allele level, we find that the hypermethylated alleles are associated with repressed expression, while the remaining unmethylated alleles are associated with active chromatin marks, and are responsible for the observed TERT expression in cancer. The association of hypomethylated alleles with active expression and hypermethylated alleles with repressed expression is particularly evident in cancers harboring promoter mutations, and cancers displaying allele specific expression.
Consistent with the findings of Stern and colleagues (22) , we find that in cancers with TERT promoter mutations, the expressed allele is the mutant allele while the silenced allele is WT.
Here in this study, we extend these findings by phasing the methylation pattern with the promoter mutation status at a single molecule level and also extent to cancer cell line models with WT TERT promoters, wherein the methylated alleles are silenced and the hypomethylated alleles are expressed.
The significance of promoter methylation in the modulation of TERT expression is perhaps best represented in the unique cases of cancer cell lines with predominantly mutated TERT promoter alleles, such as U251 and HOP62, that possess a balance of both unmethylated and methylated alleles, with open chromatin marks enriched in the unmethylated alleles. These observations suggest that even alleles with TERT promoter mutations are silenced by methylation. In our reporter assays of heterologous constructs driven by the TERT promoter, we find that introducing the highly recurrent C228T mutation increases reporter expression by approximately 2 to 3-fold, consistent with prior reports on the impact of TERT promoter mutations on gene expression (12, 41) . More importantly, we also find that methylation of these reporter constructs suppresses expression, independent of promoter status as WT or mutant.
Collectively, the findings reported here reaffirm that methylation of TERT promoter sequences is a signal of repression rather than activation of expression. The balance of methylated and unmethylated alleles in cancer cells, particularly in the cases where the majority of alleles are methylated and only a fraction of cells have unmethylated and active alleles, suggests that cancer cells behave as a plastic population of stem-like cells. Following telomerase activation, it is intriguing that cancer cells would repress TERT expression. One possibility is that repression of all TERT alleles by DNA methylation is a default tumor suppressing response in all cells post-telomerase activation, but selective pressure ensures the persistence of unmethylated alleles, as suggested by others (23) ; after all, cancer cells require some means of telomere maintenance to sustain indefinite proliferation. However, if expression and activation of TERT alleles is entirely advantageous to cancer cells, then it is unclear why cells with unmethylated alleles would not, over time, dominate the population, resulting in the majority of alleles being hypomethylated rather than what we observe here.
Another intriguing possibility is that excessive activation of TERT may have negative consequences on growth, survival or other cancer phenotypes, and as a result, there is selective advantage for fine tuning the amount of TERT activation through DNA methylation-mediated epigenetic repression of some alleles. This would explain the observation that TERT expression is relatively low in the majority of cancers, just sufficient to maintain telomere lengths that are already relatively short compared to normal cells (42, 43) . These findings thus nominate a provocative hypothesis that excessive TERT may be disadvantageous in cancer cells, and would be worthwhile to investigate in future studies. In conclusion, our findings suggest that hypermethylation of the TERT promoter alleles signals transcriptional repression of those alleles, leading to attenuation of TERT activation in cancer cells.
MATERIALS AND METHODS
Cell line Validation.
A panel of 96 cell culture models were included in this study, 85 cancer lines, 6 immortalized lines, and 5 normal primary cell models. Cell line identify was validated through STR profiling (see Table S1 . Cell Line Characteristics). The following cycling conditions were used: 1 cycle of 95°C for 3 minutes; 32 cycles of 95°C for 30 seconds, 56°C for 30 seconds, and 72°C for 40 seconds; and 1 cycle of 72°C for 5 minutes.
Preparation of bisulfite sequencing amplicon libraries
PCR products were purified using DNA Clean and Concentrator-5 columns (Zymo) and subsequently analyzed by Sanger sequencing.
Preparation of luciferase constructs for methylated/unmethylated promoter bashing.
TERT promoter regions were cloned into the pNL1. H3K27ac. Mann-Whitney test was used to assess a statistically significant difference in plots,
while Chi-square test was used in a 2x2 contingency table of TERT promoter status of allele (WT vs mutant) and GpG methylation (methylated vs unmethylated). Asterisks denote level of significance (* p ≤ 0.5, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). shows higher expression in mutants compared to wild type promoter, with activity largely abolished in methylated constructs independent of host cell mutation status.
